Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Conflicts Of Interest In Pharmaceutical Sponsored Research On Erythropoietin Receptors In Cancer: An Updated Analysis

Alyssa Trenery, Samuel Kessler, BA, Van Slooten Eleasa, BS, Akida Lebby, Charles L. Bennett, MD, PhD, MPP, Paul Yarnold, PhD, Paul Ray, DO, MA, Dennis W. Raisch, PhD, MS, RPh, Gowtham Rao, MD, PhD, Peter Georgantopoulos, MPH, MA, LeAnne Norris, PharmD, Simone Boyle, BA, Ashlyn Byrne, Matthew Bialkowski, Oliver Sartor, MD

Blood (2013) 122 (21): 2938.

https://doi.org/10.1182/blood.V122.21.2938.2938

Published: 2013

Journal Articles

Fatal and Serious Anaphylaxis Following Peginesatide Administration

Charles L. Bennett, MD, PhD, MPP, Sony Jacob, MD, Iain C Macdougall, MD, Tom Moore, Peter Georgantopoulos, MPH, MA, Judy Nichols, Paul Yarnold, PhD, Oliver Sartor, MD, Dennis W. Raisch, PhD, MS, RPh, Ashraf Mikhail, MD, LeAnn Norris, PharmD, Samuel Kessler, BA, Jametta Magwood, BA, David Goldsmith, MB, ChB

Blood (2013) 122 (21): 5612.

https://doi.org/10.1182/blood.V122.21.5612.5612

Published: 2013

Journal Articles

First Estimates of Incidence of Progressive Multifocal Leukoencephalopathy Developing Among 10,459 Non-HIV Lymphoma VA Patients Who Receive Rituximab: Results From the Veterans Administration Database (1999–2012).

Gowtham Rao, MD, PhD, Peter Georgantopoulos, MPH, AM, Kathlyn Sue Haddock, RN, PhD, Kenneth R. Carson, MD, LeAnn Norris, PharmD, Oliver Sartor, MD, Charles Bennett, MD, PhD, MPP

Blood (2012) 120 (21): 2752.

https://doi.org/10.1182/blood.V120.21.2752.2752

Published: 2012

Journal Articles

Evaluating Conflicts of Interest in Academic Research On Erythropoietin Receptors in the Cancer Setting

Charles Bennett, MD, PhD, MPP, Eleasa vanSlooten, Matthew Bialkowski, Alyssa Trenery, Ashlyn Byrne, Alanna Murday, BS, Paul Yarnold, Zaina Parvez Qureshi, PhD, MPH, A. Oliver Sartor, MD

Blood (2012) 120 (21): 4695.

https://doi.org/10.1182/blood.V120.21.4695.4695

Published: 2012

Journal Articles

Why Is Cancer Care So Expensive: Potential Implications of Fraud and Abuse

Zhiqiang Lu, Zaina Parvez Qureshi, PhD, MPH, Brian Chen, Sudha Xirasagar, Paul Ray, Gowtham Rao, Isaac Lopez, Tisha Felder, Richard Ablin, Oliver Sartor, MD, Charles Bennett, MD, PhD, MPP

Blood (2012) 120 (21): 4275.

https://doi.org/10.1182/blood.V120.21.4275.4275

Published: 2012

Journal Articles

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

Blood (2009) 113 (20): 4834–4840.

https://doi.org/10.1182/blood-2008-10-186999

Published: 2009

Journal Articles

“Getting to go” for FDA Approvals for the Treatment of Hematologic Versus Solid Tumor Malignancies: A Report from the Research on Adverse Drug Events and Reports (RADAR) Project

Elizabeth A Richey, BA, Veena Shankaran, MD, Steven Hirschfeld, MD, PhD, Steven M Trifilio, RPh, June McKoy, MD, MPH, Kenneth R Carson, MD, Beatrice J Edwards, MD, FACP, Thanh Ha Luu, BA, Narissa Nonzee, BS, A. Oliver Sartor, MD, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 2402.

https://doi.org/10.1182/blood.V112.11.2402.2402

Published: 2008

Journal Articles

Erythropoiesis Stimulating Agent (ESA) Use for Anemic Cancer and Chronic Kidney Disease (CKD) Patients in 2008: Advocacy for Conservative Use

Charles L. Bennett, MD, PhD, MPP, Benjamin Kim, MD, Athena T Samaras, BA, Allen R Nissenson, MD, FACP, A. Oliver Sartor, MD, D. Mark Courtney, MD, Robert I. Liem, MD, Dennis P West, PhD, Simone N Boyle, BA, Robin L Wagner, Carolyn E Goldstein, Steven M Trifilio, RPh, David M Spiegel, MD, FACP, Stephen Y Lai, MD, PhD

Blood (2008) 112 (11): 4680.

https://doi.org/10.1182/blood.V112.11.4680.4680

Published: 2008

Journal Articles

Evaluating Mortality with Erythropoietin Stimulating Agents (ESAs) in the Oncology Setting: The Importance of Selecting Trials That Include Survival or Loco-Regional Tumor Control as a Primary Endpoint

Athena T Samaras, BA, Sara E Barnato, MD, Benjamin Kim, MD, Stephen Y Lai, MD, PhD, A. Oliver Sartor, MD, June McKoy, MD, JD, MPH, Brian C Sauer, PhD, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 4681.

https://doi.org/10.1182/blood.V112.11.4681.4681

Published: 2008

Journal Articles

Evaluation of Conflicts of Interest in Basic Science Studies Evaluating Erythropoietin and Erythropoietin Effects of Solid Cancer Cell Lines

Sara E Barnato, MD, Simone N Boyle, BA, Adam Kuykendal, MD, Stephen Y Lai, MD, PhD, Robin L Wagner, Carolyn E Goldstein, Athena T Samaras, BA, Dennis P West, PhD, Jacob Tallman, Michael Henke, MD, A. Oliver Sartor, MD, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 672.

https://doi.org/10.1182/blood.V112.11.672.672

Published: 2008

Journal Articles

Waiting for Godot: Thirty-Six Month Follow-Up on Accelerated FDA Approval of Drugs To Treat Hematologic Malignancies.

Veena Shankaran, MD, June McKoy, MD, MPH, JD, Ben Djulbegovic, MD, PhD, Allison Lyons, BA, Ken Carson, MD, Cara Tigue, BA, Neal Dandade, BA, Martin Tallman, MD, Oliver Sartor, MD, Charles Bennett, MD, PhD, MPP

Blood (2007) 110 (11): 3340.

https://doi.org/10.1182/blood.V110.11.3340.3340

Published: 2007

NARROW

Conflicts Of Interest In Pharmaceutical Sponsored Research On Erythropoietin Receptors In Cancer: An Updated Analysis

Fatal and Serious Anaphylaxis Following Peginesatide Administration

First Estimates of Incidence of Progressive Multifocal Leukoencephalopathy Developing Among 10,459 Non-HIV Lymphoma VA Patients Who Receive Rituximab: Results From the Veterans Administration Database (1999–2012).

Evaluating Conflicts of Interest in Academic Research On Erythropoietin Receptors in the Cancer Setting

Why Is Cancer Care So Expensive: Potential Implications of Fraud and Abuse

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

“Getting to go” for FDA Approvals for the Treatment of Hematologic Versus Solid Tumor Malignancies: A Report from the Research on Adverse Drug Events and Reports (RADAR) Project

Erythropoiesis Stimulating Agent (ESA) Use for Anemic Cancer and Chronic Kidney Disease (CKD) Patients in 2008: Advocacy for Conservative Use

Evaluating Mortality with Erythropoietin Stimulating Agents (ESAs) in the Oncology Setting: The Importance of Selecting Trials That Include Survival or Loco-Regional Tumor Control as a Primary Endpoint

Evaluation of Conflicts of Interest in Basic Science Studies Evaluating Erythropoietin and Erythropoietin Effects of Solid Cancer Cell Lines

Waiting for Godot: Thirty-Six Month Follow-Up on Accelerated FDA Approval of Drugs To Treat Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only